Volume 37, Issue 12 pp. 1966-1976
Systematic Review or Meta-analysis

Distal technology interventions in people with diabetes: an umbrella review of multiple health outcomes

P. Chakranon

P. Chakranon

Faculty of Pharmacy, Silapakorn University, Pathom, Thailand

Search for more papers by this author
Y. K. Lai

Y. K. Lai

Department of Pharmacy, Hospital Universiti Kebangsaan Malaysia, Cheras, Malaysia

Search for more papers by this author
Y. W. Tang

Y. W. Tang

School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia

Search for more papers by this author
P. Choudhary

P. Choudhary

Department of Diabetes, School of Life Course Sciences, King's College London, London, UK

Search for more papers by this author
K. Khunti

K. Khunti

Diabetes Research Centre, University of Leicester, Leicester, UK

Search for more papers by this author
S. W. H. Lee

Corresponding Author

S. W. H. Lee

School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia

Asian Centre for Evidence Synthesis in Population, Implementation and Clinical Outcomes (PICO), Health and Well-being Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University Malaysia, Selangor, Malaysia

School of Pharmacy, Taylor's University Lakeside Campus, Jalan Taylors, Selangor, Malaysia

Correspondence to: Shaun Wen Huey Lee. E-mail: [email protected]Search for more papers by this author
First published: 20 October 2019
Citations: 13
(PROSPERO study registration number: CRD42018084577)

Abstract

Aim

To summarize and evaluate the existing evidence on the effectiveness of distal technology with regard to multiple health outcomes in people with diabetes.

Methods

We searched PubMed, EMBASE and the Cochrane Database of Systematic Reviews from database inception to 31 August 2018 for systematic reviews and/or meta-analyses of studies that examined the impact of distal technology and reported any clinical or patient-related outcomes among people with type 1 or type 2 diabetes.

Results

The umbrella review identified 95 reviews, including 162 meta-analyses with 46 unique outcomes. Evidence from meta-analyses of randomized controlled studies supports the use of distal technology, especially telehealth and mHealth (healthcare delivered by mobile technology), in people with diabetes for improving HbA1c values by 2–4 mmol/mol (0.2–0.4%). For other health outcomes, such as changes in fasting plasma glucose levels, risk of diabetic ketoacidosis or frequency of severe hypoglycaemia, the evidence was weaker. No evidence was reported for most patient-reported outcomes including quality of life, self-efficacy and medication-taking. The evidence base was poor, with most studies rated as low to very low quality.

Conclusion

Distal technologies were associated with a modest improvement in glycaemic control, but it was unclear if they improved major clinical outcomes or were cost-effective in people with diabetes. More robust research to improve wider outcomes in people with diabetes is needed before such technologies can be recommended as part of routine care for any patient group.

Data availability statement

All data generated and analysed in this study are available from the corresponding author on reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.